ELISA (EIA)
(The Binding Activity of SARS-CoV-2-S Antibody with SARS-CoV-2-S1-RBD Activity: Measured by its binding ability in a functional ELISA. Immobilized SARS-CoV-2-S1-RBD (MBS7135911) at 2 ug/ml can bind SARS-CoV-2-S Antibody, the EC50 is 0.8674 ng/ml.)
COVID 19 Spike RBD Coronavirus Recombinant Antibody | COVID-19 recombinant antibody
SARS-CoV-2 Spike RBD Nanobody
GICA: 1:10,000-1:40,000
Neutralising: 1:100-1:10,000
Constituents: 50% Glycerol, 0.01M PBS, PH7.4
ELISA (EIA)
(The Binding Activity of SARS-CoV-2-S Antibody with SARS-CoV-2-S1-RBD Activity: Measured by its binding ability in a functional ELISA. Immobilized SARS-CoV-2-S1-RBD (MBS7135911) at 2 ug/ml can bind SARS-CoV-2-S Antibody, the EC50 is 0.8674 ng/ml.)
ELISA (EIA)
(The Binding Activity of SARS-CoV-2-S Antibody with SARS-CoV-2-S1-RBD Activity: Measured by its binding ability in a functional ELISA. Immobilized SARS-CoV-2-S1-RBD (MBS7135911) at 2 ug/ml can bind SARS-CoV-2-S Antibody, the EC50 is 0.8674 ng/ml.)
Testing Data
(GICA In the Colloidal Gold Immunochromatography Assay detection system, the background of antibody (MBS7136646) is clean, the detection limit can be as low as 25ng/ml (1.75ng/0.07ml), and the sensitivity is very good.)
Testing Data
(GICA In the Colloidal Gold Immunochromatography Assay detection system, the background of antibody (MBS7136646) is clean, the detection limit can be as low as 25ng/ml (1.75ng/0.07ml), and the sensitivity is very good.)
Testing Data
(SARS-CoV-2 Spike RBD Nanobody (MBS7136646) competed with ACE2-HRP conjugate (MBS1422789 ) for binding to SARSCoV-2-S1-RBD (MBS7135911). The binding signal of SARS-CoV-2-S1-RBD and ACE2-HRP conjugate was gradually reduced as the SARSCoV- 2 Spike RBD Nanobody concentrations increased. It indicated that this SARS-CoV-2 Spike RBD Nanobody effectively inhibited the SARS-CoV-2-S1-RBD/ACE2 binding. And the IC50 of this SARS-CoV-2 Spike RBD Nanobody is 1.296 nM.)
Testing Data
(SARS-CoV-2 Spike RBD Nanobody (MBS7136646) competed with ACE2-HRP conjugate (MBS1422789 ) for binding to SARSCoV-2-S1-RBD (MBS7135911). The binding signal of SARS-CoV-2-S1-RBD and ACE2-HRP conjugate was gradually reduced as the SARSCoV- 2 Spike RBD Nanobody concentrations increased. It indicated that this SARS-CoV-2 Spike RBD Nanobody effectively inhibited the SARS-CoV-2-S1-RBD/ACE2 binding. And the IC50 of this SARS-CoV-2 Spike RBD Nanobody is 1.296 nM.)
Testing Data
(SARS-CoV-2 Spike RBD Nanobody(MBS7136646) competitively prevented SARS-CoV-2-S1-RBD (MBS7135911) from binding to ACE2-HRP conjugate (MBS1422789). The inhibition efficacy of the SARS-CoV-2-S1-RBD/ACE2 binding was positively proportionally to the SARSCoV- 2 Spike RBD Nanobody concentrations. It showed that this SARS-CoV-2 Spike RBD Nanobody effectively inhibited the SARS-CoV-2-S1- RBD/ACE2 binding. And the IC50 of this SARSCoV- 2 Spike RBD Nanobody is 0.1074 g/ml.)
Testing Data
(SARS-CoV-2 Spike RBD Nanobody(MBS7136646) competitively prevented SARS-CoV-2-S1-RBD (MBS7135911) from binding to ACE2-HRP conjugate (MBS1422789). The inhibition efficacy of the SARS-CoV-2-S1-RBD/ACE2 binding was positively proportionally to the SARSCoV- 2 Spike RBD Nanobody concentrations. It showed that this SARS-CoV-2 Spike RBD Nanobody effectively inhibited the SARS-CoV-2-S1- RBD/ACE2 binding. And the IC50 of this SARSCoV- 2 Spike RBD Nanobody is 0.1074 g/ml.)
Testing Data
(SARS-CoV-2 Spike protein RBD His/Sumostar Tag (MBS7135911) captured on COOH chip binding to the SARS-CoV-2 Spike RBD Nanobody (MBS7136646), increases the local refractive index (RI), leading to a red shift of the LSPR peak position. The higher concentrations of SARS-CoV-2 Spike RBD Nanobody, the larger the wavelength shift. The detected affinity constant of SARS-CoV-2 Spike protein RBD/SARS-CoV-2 Spike RBD Nanobody binding is 28.2nM.)
Testing Data
(SARS-CoV-2 Spike protein RBD His/Sumostar Tag (MBS7135911) captured on COOH chip binding to the SARS-CoV-2 Spike RBD Nanobody (MBS7136646), increases the local refractive index (RI), leading to a red shift of the LSPR peak position. The higher concentrations of SARS-CoV-2 Spike RBD Nanobody, the larger the wavelength shift. The detected affinity constant of SARS-CoV-2 Spike protein RBD/SARS-CoV-2 Spike RBD Nanobody binding is 28.2nM.)
Testing Data
(ELISA: Immobilize various types of SARS proteins at concentration of 2mg/ml on solid substrate, then react with SARS-CoV-2 Spike RBD Nanobody at concentration of 100mg/ml, 10mg/ml and 1mg/ml. It shows the SARS-CoV-2 Spike RBD Nanobody (MBS7136646) is specific for SARS-CoV-2-S1-RBD protein, without any cross-reactivity with MERS-CoV, SARS-CoV, HCoV-OC43 or HCoV-229E.)
Testing Data
(ELISA: Immobilize various types of SARS proteins at concentration of 2mg/ml on solid substrate, then react with SARS-CoV-2 Spike RBD Nanobody at concentration of 100mg/ml, 10mg/ml and 1mg/ml. It shows the SARS-CoV-2 Spike RBD Nanobody (MBS7136646) is specific for SARS-CoV-2-S1-RBD protein, without any cross-reactivity with MERS-CoV, SARS-CoV, HCoV-OC43 or HCoV-229E.)
It is also validated in Neutralizing and LSPR. In neu assay, the binding signal of the SARS-CoV-2 S1 RBD antibody was inhibited by ACE2 protein-HRP conjugated inhibitor, with a 0.1074 mg/ml IC50. In LSPR assay, the SARS-CoV-2 S1 RBD antibody showed a high affinity with SARS-CoV-2 Spike protein RBD (affinity constant: 28.2nM).
Specifically binding and recognizing the RBD of the SARS-CoV-2 spike glycoprotein, the SARS-CoV-2 S1 RBD antibody can react with samples infected with human coronavirus SARS-CoV-2. But it does not respond to MERS or SARS-CoV spike protein. Akin to other nanobodies, this recombinant nanobody is small and stable, which allows for its reaching to hidden epitopes such as crevices of target proteins.
NCBI and Uniprot Product Information
Similar Products
Product Notes
The COVID-19 (Catalog #AAA7136646) is a Recombinant Antibody produced from Rabbit and is intended for research purposes only. The product is available for immediate purchase. The SARS-CoV-2 Spike RBD Nanobody reacts with Human Novel Coronavirus (SARS-CoV-2/ 2019-nCoV) and may cross-react with other species as described in the data sheet. AAA Biotech's COVID 19 Spike RBD Coronavirus can be used in a range of immunoassay formats including, but not limited to, ELISA (EIA), Colloidal Gold Immunochromatographic Assay (GICA), Neutralising. ELISA: 1:10,000-1:100,000 GICA: 1:10,000-1:40,000 Neutralising: 1:100-1:10,000. Researchers should empirically determine the suitability of the COVID-19 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "COVID 19 Spike RBD Coronavirus, Monoclonal Recombinant Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
